Pulse Biosciences (NASDAQ:PLSE) Share Price Crosses Below Fifty Day Moving Average – Here’s What Happened

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $17.87 and traded as low as $17.27. Pulse Biosciences shares last traded at $17.30, with a volume of 92,403 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research note on Friday, September 20th.

Pulse Biosciences Stock Down 2.6 %

The firm has a market capitalization of $955.39 million, a price-to-earnings ratio of -21.36 and a beta of 1.74. The firm’s 50 day moving average is $17.87 and its 200 day moving average is $13.66.

Institutional Trading of Pulse Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning lifted its stake in Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after purchasing an additional 11,667 shares during the last quarter. Quest Partners LLC acquired a new stake in Pulse Biosciences during the second quarter valued at approximately $91,000. Rhumbline Advisers lifted its stake in Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after purchasing an additional 9,639 shares during the last quarter. Finally, Westside Investment Management Inc. lifted its stake in Pulse Biosciences by 97.8% during the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after purchasing an additional 31,440 shares during the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.